Abstract
The prognosis of patients diagnosed with peritoneal metastasized (PM) colorectal cancer who are ineligible for cytoreductive surgery (CRS) in combination with hyperthermic intraperitoneal chemotherapy (HIPEC) is poor. We hypothesize that adding intraperitoneal (IP) irinotecan to standard systemic palliative chemotherapy improves the prognosis of these patients. Therefore we conducted this phase I trial.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
